Novavax (NVAX) makes a public offer to acquire all outstanding shares of Isconova, a...

|By:, SA News Editor

Novavax (NVAX) makes a public offer to acquire all outstanding shares of Isconova, a Sweden-based company which makes vaccine adjuvants and has an impressive list of big pharma partners. The all-stock deal is worth~$29.6M. (PR)